拟抗体 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "拟抗体" in Chinese language version.

refsWebsite

Global rank Chinese rank

10nih.gov

4^th place

5^th place

8doi.org

2^nd place

23^rd place

3elsevier.com

610^th place

388^th place

3web.archive.org

1^st place

1archive.org

6^th place

4^th place

archive.org

Silverman J, Liu Q, Lu Q; et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat. Biotechnol. December 2005, 23 (12): 1556–61. PMID 16299519. doi:10.1038/nbt1166.

doi.org

Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol. June 2009, 13 (3): 245–255 [2011-09-14]. PMID 19501012. doi:10.1016/j.cbpa.2009.04.627. （原始内容存档于2019-11-29）.
Nygren PA. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J. June 2008, 275 (11): 2668–76. PMID 18435759. doi:10.1111/j.1742-4658.2008.06438.x.
Ebersbach H, Fiedler E, Scheuermann T; et al. Affilin-novel binding molecules based on human gamma-B-crystallin, an all beta-sheet protein. J. Mol. Biol. September 2007, 372 (1): 172–85. PMID 17628592. doi:10.1016/j.jmb.2007.06.045.
Krehenbrink M, Chami M, Guilvout I, Alzari PM, Pécorari F, Pugsley AP. Artificial binding proteins (Affitins) as probes for conformational changes in secretin PulD. J. Mol. Biol. November 2008, 383 (5): 1058–68 [2011-09-14]. PMID 18822295. doi:10.1016/j.jmb.2008.09.016. （原始内容存档于2019-11-30）.
Skerra A. Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J. June 2008, 275 (11): 2677–83. PMID 18435758. doi:10.1111/j.1742-4658.2008.06439.x.
Silverman J, Liu Q, Lu Q; et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat. Biotechnol. December 2005, 23 (12): 1556–61. PMID 16299519. doi:10.1038/nbt1166.
Stumpp MT, Binz HK, Amstutz P. DARPins: a new generation of protein therapeutics. Drug Discov. Today. August 2008, 13 (15–16): 695–701 [2011-09-14]. PMID 18621567. doi:10.1016/j.drudis.2008.04.013. （原始内容存档于2019-12-01）.
Grabulovski D; Kaspar, M; Neri, D. A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties. J Biol Chem. 2007, 282 (5): 3196–3204. PMID 17130124. doi:10.1074/jbc.M609211200.

elsevier.com

linkinghub.elsevier.com

Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol. June 2009, 13 (3): 245–255 [2011-09-14]. PMID 19501012. doi:10.1016/j.cbpa.2009.04.627. （原始内容存档于2019-11-29）.
Krehenbrink M, Chami M, Guilvout I, Alzari PM, Pécorari F, Pugsley AP. Artificial binding proteins (Affitins) as probes for conformational changes in secretin PulD. J. Mol. Biol. November 2008, 383 (5): 1058–68 [2011-09-14]. PMID 18822295. doi:10.1016/j.jmb.2008.09.016. （原始内容存档于2019-11-30）.
Stumpp MT, Binz HK, Amstutz P. DARPins: a new generation of protein therapeutics. Drug Discov. Today. August 2008, 13 (15–16): 695–701 [2011-09-14]. PMID 18621567. doi:10.1016/j.drudis.2008.04.013. （原始内容存档于2019-12-01）.

nih.gov

ncbi.nlm.nih.gov

Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol. June 2009, 13 (3): 245–255 [2011-09-14]. PMID 19501012. doi:10.1016/j.cbpa.2009.04.627. （原始内容存档于2019-11-29）.
Nygren PA. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J. June 2008, 275 (11): 2668–76. PMID 18435759. doi:10.1111/j.1742-4658.2008.06438.x.
Ebersbach H, Fiedler E, Scheuermann T; et al. Affilin-novel binding molecules based on human gamma-B-crystallin, an all beta-sheet protein. J. Mol. Biol. September 2007, 372 (1): 172–85. PMID 17628592. doi:10.1016/j.jmb.2007.06.045.
Krehenbrink M, Chami M, Guilvout I, Alzari PM, Pécorari F, Pugsley AP. Artificial binding proteins (Affitins) as probes for conformational changes in secretin PulD. J. Mol. Biol. November 2008, 383 (5): 1058–68 [2011-09-14]. PMID 18822295. doi:10.1016/j.jmb.2008.09.016. （原始内容存档于2019-11-30）.
Skerra A. Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J. June 2008, 275 (11): 2677–83. PMID 18435758. doi:10.1111/j.1742-4658.2008.06439.x.
Silverman J, Liu Q, Lu Q; et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat. Biotechnol. December 2005, 23 (12): 1556–61. PMID 16299519. doi:10.1038/nbt1166.
Stumpp MT, Binz HK, Amstutz P. DARPins: a new generation of protein therapeutics. Drug Discov. Today. August 2008, 13 (15–16): 695–701 [2011-09-14]. PMID 18621567. doi:10.1016/j.drudis.2008.04.013. （原始内容存档于2019-12-01）.
Grabulovski D; Kaspar, M; Neri, D. A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties. J Biol Chem. 2007, 282 (5): 3196–3204. PMID 17130124. doi:10.1074/jbc.M609211200.
Nixon AE, Wood CR. Engineered protein inhibitors of proteases. Curr Opin Drug Discov Devel. March 2006, 9 (2): 261–8. PMID 16566296.
Koide A, Koide S. Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. Methods Mol. Biol. 2007, 352: 95–109. PMID 17041261.

web.archive.org

Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol. June 2009, 13 (3): 245–255 [2011-09-14]. PMID 19501012. doi:10.1016/j.cbpa.2009.04.627. （原始内容存档于2019-11-29）.
Krehenbrink M, Chami M, Guilvout I, Alzari PM, Pécorari F, Pugsley AP. Artificial binding proteins (Affitins) as probes for conformational changes in secretin PulD. J. Mol. Biol. November 2008, 383 (5): 1058–68 [2011-09-14]. PMID 18822295. doi:10.1016/j.jmb.2008.09.016. （原始内容存档于2019-11-30）.
Stumpp MT, Binz HK, Amstutz P. DARPins: a new generation of protein therapeutics. Drug Discov. Today. August 2008, 13 (15–16): 695–701 [2011-09-14]. PMID 18621567. doi:10.1016/j.drudis.2008.04.013. （原始内容存档于2019-12-01）.